---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-007369"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:51:29.463929+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cyclerion reports Q1 net loss $13.0M; CY6463 MELAS data expected Q2 2022

## Summary
- Net loss of $13.0M in Q1 2022 vs $13.4M in Q1 2021; cash balance $41M (down from $54M).
- R&D expenses rose to $9.7M from $8.0M due to external research costs; G&A fell to $4.0M from $5.4M.
- MELAS study enrollment closed; topline data expected Q2 2022.
- CIAS study enrollment closed; topline data expected Q3 2022.
- Alzheimer's disease with vascular pathology (ADv) study enrollment ongoing.

## SEC filing metadata
- accession: 0000950170-22-007369
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017022007369/0000950170-22-007369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017022007369/cycn-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-007369
- JSON: https://secwatch.observer/filing/0000950170-22-007369.json
- Plain text: https://secwatch.observer/filing/0000950170-22-007369.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.